Rocket Pharma在出售优先审查凭证后更新现金状况

2026-06-12 19:31

Rocket Pharmaceuticals (RCKT) on Friday disclosed more than $320M in cash, cash equivalents, and investments pro forma after completing the previously disclosed sale of its rare pediatric disease priority review voucher.
In April, the company announced $180M in potential gross proceeds after agreeing to sell the PRV, which it received following FDA approval of its gene therapy, Kresladi, for a rare immune disease called leukocyte adhesion deficiency-I earlier this year.
On Friday, the Cranbury, New Jersey-based biotech said it has completed the sale, and as a result, its cash, cash equivalents, and investments, which stood at $144.4M as of March 31, will rise to roughly $322.6M.
The non-dilutive capital from the PRV sale will help it extend its cash runway through Q2 2028, the company added.

More on Rocket Pharmaceuticals